Johnson & Johnson Announces U.S. Food and Drug Administration Approves AKEEGA as the First Precision Therapy for BRCA2-Mutated Metastatic Castration-sensitive Prostate Cancer with 54% Reduction in Disease Prostate Cancer with 54% reduction in Disease Prostate Cancer
Kort samengevat
Johnson & Johnson announced the U.S. Food and Drug Administration approved the supplemental New Drug Application for AKEEGA®? plus prednisone for the treatment of patients with BRCA2-mutated...
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij MarketScreener.
Lees het volledige bericht ↗